Abstract
Tumoral hypoxia is related to severe structural abnormalities of tumor microvessels, leading to deteriorated O2 diffusion. This decreased O2 concentration in cancer cells compromises cellular functions, besides being responsible for resistance to radiation therapy. Consequently, it is very important to know the hypoxic status of a tumor. In this review, the different methodologies available for evaluating cellular hypoxia in vivo are discussed, particularly those in which the hypoxia information is obtained through imaging. Among these the nuclear medicine approach uses ligands to complex with radionuclides. The resulting radioactive complexes which may be single photon or positron emitters, are very useful as imaging probes. The nature of ligands and their corresponding complexes, with application or potential application as hypoxia detectors, will be described. A summary of the most significant results so far obtained in clinical or pre-clinical applications will also be discussed.
Similar content being viewed by others
References
Abele D (2002) Toxic oxygen: the radical life-giver. Nature 420: 27
Clarkson AN, Sutherland BA, Appleton I (2005) The biology and pathology of hypoxia-ischemia:an update. Arch Immunol Ther Exp (Warsz) 53:213–225
Mariani E, Polidori MC, Cherubini A, Mecocci P (2005) Oxidative stress in brain aging, neurodegenerative and vascular diseases: an overview. J Chromatogr B Anal Technol Biomed Life Sci 827:65–75
Shannon AM, Bouchier-Hayes DJ, Condron CM, Toomey D (2003) Tumor hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat Rev 29:297–307
Semenza GL (2001) HIF-1, O2, and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 107:1–3
West JB (1999) Respiratory physiology—the essentials. 6th edn. Williams & Wilkins, Baltimore
Hockel M, Vaupel P (2001) Tumour hypoxia: definitions and current clinical, biologic and molecular aspects. J Natl Cancer Inst 93:266–276
Boyer PD, Chance B, Ernster L et al (1977) Oxidative phosphorylation and photophosphorylation. Annu Rev Biochem 46:955–1026
Honig CR (1985) Modern cardiovascular physiology, 2nd edn. Little and Brown, Boston. 1988
Zander R, Vaupel P (1985) Proposal for using a standardized terminology on oxygen transport to tissue. Adv Exp Med Biol 191:965–970
Glossary on respiration and gas exchange (1973) J Appl Physiol 34:549–558
Vaupel P, Kallinowski F, Okunieff P (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49:6449–6465
Vaupel P, Fortmeyer HP, Runkel S (1987) Blood flow, oxygen consumption, and tissue oxygenation of human breast cancer xenografts in nude rats. Cancer Res 47:3496–3503
Kallinowski F, Schlenger KH, Runkel S et al (1989) Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts. Cancer Res 49:3759–3764
Harris AL (2002) Hypoxia—a key regulatory factor in tumor growth. Nat Rev Cancer 2:38–47
Gray LH, Conger AD, Ebert M (1953) The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26:638–648
Kisaka-Kondoh S, Inoue M, Harada H, Hiraoka M (2003) Tumor hypoxia: a target for selective cancer therapy. Cancer Sci 94:1021–1028
Jain RK (1998) Determinants of tumor blood flow: a review. Cancer Res 48:2641–2658
Yu JL, Rak JW, Carmeliet P et al (2001) Heterogenous vascular dependence of tumor cell populations. Am J Pathol 158:1325–1334
Vaupel P, Thews O, Hoeckel M (2001) Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 18:243–259
Vaupel P, Kelleher DK, Hockel M (2001) Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 28(Suppl 8):29–35
Vaupel P, Briest S, Hockel M (2002) Hypoxia in breast cancer: pathogenesis, characterization and biological/therapeutic implications. Wien Med Wochenschr 152:334–342
Blankenberg FG, Strauss HW (2007) Nuclear medicine applications in molecular imaging: 2007 update. Quart J Nuclear Med Mol Imaging 51:99–110
Airley R E, Mobasheri A (2007) Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 53:233–256
Helminger G, Yuan F, Dellian M, Jain RK (1997) Interstitial pH and pO2 gradients in solid tumors in vivo: high resolution measurements reveal a lack of correlation. Nat Med 3:177–182
Pouysségur J, Dayan F, Mazure NM (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441:437–443
Coleman CN, Mitchell JB, Camphausen K (2002) Tumor hypoxia: chicken, egg, or a piece of the farm? J Clin Oncol 20:610–615
Vaupel P, Harrison L (2004) Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 9:4–9
Horsman MR, Overgaard J (2002) The oxygen effect and tumor microenvironment. In: Steel GG (ed) Basic clinical radiobiology, vol 26. Arnold, London, pp 281–290
Padhani AR, Krohn KA, Lewis JS, Alber M (2007) Imaging oxygenation of human tumors. Eur Radiol 17:861–872
Schwarz G (1909) Uber desensibilisierung gegen Rontgen- und Radiumstrahlen. Munchener Med Wochenschr 24:1–2
Mottram JC (1931) A factor of importance in the radio-sensitivity of tumors. Br J Radiol 9:606–614
Vikram DS, Zweier JL, Kuppusamy P (2007) Methods for noninvasive imaging of tissue hypoxia. Antioxid Redox Signal 10:1745–1755
Vaupel P, Kelleher DK (eds) (1999) Tumor hypoxia: pathophysiology, clinical significance and therapeutic perspectives. Wissenschaftliche Verlagsgesellschaft, Stuttgart
Stone HB, Brown JM, Philips TL, Sutherland RM (1993) Oxygen in human tumors: correlations between methods of measurement and response to therapy. Summary of a workshop held November 19–20, 1992 at the National Cancer Institute, Bethesda, Maryland. Radiat Res 136:422–434
Olive PL, Banath JP, Aquino-Parsons C (2001) Measuring hypoxia in solid tumors—is there a gold standard? Acta Oncol 40:917–923
Nozue M, Lee I, Yuan F et al (1997) Interlaboratory variation in oxygen tension measurement by Eppendorf ‘Histograph’ and comparison with hypoxic marker. J Surg Oncol 66:30–38
Buerk DG (2004) Measuring tissue pO2 with microelectrodes. Methods Enzymol 381:665–690
Menon C, Fraker DL (2005) Tumor oxygenation status as a prognostic marker. Cancer Lett 221:225–235
Arbeit JM, Brown JM, Chao KS et al (2006) Hypoxia: importance in tumor biology, non-invasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 82:699–757
Vaupel P, Thews O, Kelleher DK, Konerding MA (2003) O(2) extraction is a key parameter determining the oxygenation status of malignant tumors and normal tissues. Int J Oncol 22:795–798
Griffiths JR, Robinson SP (1999) The OxyLite: a fibre-optic oxygen sensor. Br J Radiol 72:627–630
Raleigh JA, Miller GG, Franko AJ et al (1987) Fluorescence immunohistochemical detection of hypoxic cells in spheroids and tumors. Br J Cancer 56:395–400
Koch CJ (2002) Measurement of absolute oxygen levels in cells and tissues using oxygen sensors and 2-nitroimidazole EF5. Methods Enzymol 352:3–31
Hedley D, Pintilie M, Woo J et al (2003) Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. Clin Cancer Res 9:5666–5674
Ljungkvist AS, Bussink J, Rijken PF (2002) Vascular architecture, hypoxia, and proliferation in first-generation xenografts of human head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 54:215–228
Rijken PF, Bernsen HJ, Peters JP (2000) Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft: a quantitative multi-parameter analysis. Int J Radiat Oncol Biol Phys 48:571–582
Raleigh JA, Chou SC, Arteel GE (1999) Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat Res 151:580–589
Ivanov S, Liao SY, Ivanova A (2001) Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158:905–919
Laderoute KR, Grant TD, Murphy BJ (1992) Enhanced epidermal growth factor receptor synthesis in human squamous carcinoma cells exposed to low levels of oxygen. Int J Cancer 52:428–432
Grandis JR, Melhem MF, Gooding WE (1998) Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90:824–832
Moscatello DK, Holgado-Madruga M, Godwin AK (1995) Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 55:5536–5539
Forsythe JA, Jiang BH, Iyer NV (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16:4604–4613
Dunst J, Stadler P, Becker A (2001) Tumor hypoxia and systemic levels of vascular endothelial growth factor (VEGF) in head and neck cancers. Strahlenther Onkol 177:469–473
Jobsis FF (1977) Noninvasive, infrared monitoring of cerebral and myocardial oxygen sufficiency and circulatory parameters. Science 198:1264–1267
Intes X, Chance B (2005) Non-PET functional imaging techniques: optical. Radiol Clin North Am 43(XII):221–234
Boushel R, Langberg H, Olesen J et al (2001) Monitoring tissue oxygen availability with near infrared spectroscopy (NIRS) in health and disease. Scand J Med Sci Sports 11:213–222
Howe FA, Robinson SP, McIntyre DJ et al (2001) Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumors. NMR Biomed 14:497–506
Taylor JS, Tofts PS, Port R et al (1999) MR imaging of tumor microcirculation: promise for the new millennium. J Magn Reson Imaging 10:903–907
Halpern HJ, Yu C, Peric M et al (1994) Oxymetry deep in tissues with low-frequency electron paramagnetic resonance. Proc Natl Acad Sci USA 91:13047–13051
Swartz HM, Clarkson RB (1998) The measurement of oxygen in vivo using EPR techniques. Phys Med Biol 43:1957–1975
Swartz HM, Walczak T (1998) Developing in vivo EPR oximetry for clinical use. Adv Exp Med Biol 454:243–252
Loncaster JA, Carrington BM, Skyes JR et al (2002) Prediction of radiotherapy outcome using dynamic contrast enhanced MRI of carcinoma of the cervix. Int J Radiat Oncol Biol Phys 54:759–767
Krausse BJ, Beck R, Souvatzoglou M, Piert M (2006) PET and PET/CT studies of tumor tissue oxygenation. Q J Nucl Med Mol Imaging 50:28–43
Warburg O (1956) On the origin of the cancer cells. Science 123:309–314
Ballinger JR (2001) Imaging hypoxia in tumors. Semin Nucl Med 31:321–329
Jurisson SS, Lydon JD (1999) Potential technetium small molecule radiopharmaceuticals. Chem Rev 99:2205–2218
Reichert DE, Lewis JS, Anderson CJ (1999) Metal complexes as diagnostic tools. Coord Chem Rev 184:3–66
Méndez-Rojas MA, Kharisov BI, Tsivadze AY (2006) Recent advances on technetium complexes: coordination chemistry and medical applications. J Coord Chem 59:1–63
Zhuang ZP, Plössl K, Kung MP et al (1999) Neutral and stereospecific Tc-99m complexes: [99mTc]N-benzyl-3,4-di-(N-mercaptoethyl)-amino-pyrrolidines (P-BAT). Nucl Med Biol 26:217–224
Mallia MB, Subramanian S, Banerjee S et al (2006) Evaluation of 99mTc(CO)3 complex of 2-methyl-5-nitroimidazole as an agent for targeting tumor hypoxia. Bioorg Med Chem 14:7666–7670
Chapman JD (1979) Current concepts in cancer. Hypoxia sensitizers-implications for radiation therapy. N Eng J Med 301:1429–1432
Nunn A, Linder K, Strauss HW (1995) Nitroimidazole and imaging hypoxia. Eur J Nucl Med 22:265–280
Raju N, Ramalingam K, Nowotnik DP (1992) Syntheses of some nitroimidazole substituted boronic acids: precursors to technetium-99m complexes with potential for imaging hypoxic tissue. Tetrahedron 48:10233–10238
Hodgkiss R (1998) Use of 2-nitroimidazoles as bioreductive markers for tumor hypoxia. Anticancer Drug Des 13:687–702
Rauth AM, Melo T, Misra V (1998) Bioreductive therapies: an overview of drugs and their mechanisms of action. Int J Radiat Oncol Biol Phys 42:755–762
Krohn KA, Link JM, Mason RP (2008) Molecular imaging of hypoxia. J Nucl Med 49:129S–148S
Strauss HW, Nunn A, Linder K (1995) Nitroimidazoles for imaging hypoxic myocardium. J Nucl Cardiol 2:437–445
Linder KE, Chan YW, Cyr JE et al (1993) Synthesis, characterization, and in vitro evaluation of nitroimidazole-BATO complexes: new technetium compounds designed for imaging hypoxic tissue. Bioconj Chem 4:326–333
Nunn AD, Feld TA, Treher EN (1987) Boronic acid adducts of technetium-99m dioxime complexes. US Patent 4,705,849, 10 Nov 1987
Treher EN, Francesconi LC, Gougoutas JZ et al (1989) Mono-capped tris(dioxime) complexes of technetium (III): synthesis and structural characterization of TcX(dioxime)3B-R(X=Cl, Br, dioxime dimethylglyoxime cyclohexanedione dioxime; R=CH3,C4H9). Inorg Chem 28:3411–3416
Narra RK, Nunn AD, Kuczynski BL et al (1989) A neutral technetium-99m complex for myocardial imaging. J Nucl Med 30:1830–1837
Linder KE, Chan YW, Cyr JE et al (1994) 99TcO(PnAO-1-2-nitroimidazole) [BMS-181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: synthesis, characterization and xanthine oxidase-catalyzed reduction. J Med Chem 37:9–17
Ramalingam K, Raju N, Nanjappan P, Nowotnik DP (1995) Synthesis of nitroimidazole substituted 3,3,9,9-tetramethyl-4,8-diazaundecane-2,10-dione dioximes (propylene amine oximes, PnAOs): ligands for technetium-99m complexes with potential for imaging hypoxic tissue. Tetrahedron 51:2875–2894
Linder KE, Cyr JE, Chan Y-W et al (1994) Effect of substituents on physiochemical and biological behavior of Tc-PnAO nitroimidazoles. J Nucl Med 35:18P
Nanjappann P, Raju N, Ramalingam K, Nowotnik DP (1994) An efficient synthesis of some 6-substituted 4,8.diaza-3,3,9,9-tetramethylundeca-2,10-dione dioximes (propylene amine oximas, PnAOs): ligands for 99mTc complexes used in structure distribution relationship (SDR) studies. Tetrahedron 50:8617–8632
Archer CM, Binke JF, Canning LR et al (1999) Radiometal complexes that localize in hypoxic tissue. US Patent 5,997,843, 7 Dec 1999
Linder K, Nunn AD, Nowotnik DP et al (2005) Rhenium and technetium complexes containing a hypoxia-localizing moiety. US Patent 6,958,141 B2, 25 Oct 2005
Xu H, Chu T, Wang X, Liu X (2005) Facile synthesis of bis(hydroxyamamide) based tetradentate ligands for 99mTc-radiopharmaceutical. Appl Radiat Isot 62:919–922
Ramalingam K (2005) Methods of synthesizing heteroatom-bearing ligands and intermediate used thereof. US Patent 6,933,391 B2, 23 Aug 2005
Zhang X, Melo T, Rauth AM, Ballinger JR (2001) Cellular accumulation and retention of the technetium-99m-labelled hypoxia markers BRU59-21 and butylene amine oxime. Nucl Med Biol 28:949–957
Melo T, Duncan J, Balinger JR, Rauth AM (2000) BRU59-21 a second-generation 99mTc-labeled 2-nitroimidazole for imaging hypoxia in tumors. J Nucl Med 41:169–176
Hoebers FJP, Janssen HLK, Olmos RAV et al (2002) Phase 1 study to identify tumor hypoxia in patients with head and neck cancer using technetium-99m BRU 59-21. Eur J Nucl Med 29:1206–1211
Murugesen S, Shetty SJ, Noronha OPD et al (2001) Technetium-99m-cyclam AK 2123: a novel marker for tumor hypoxia. Appl Radiat Isot 54:81–88
Liang X, Sadler PJ (2004) Cyclam complexes and their applications in medicine. Crit Rev 33:246–266
Kinuya S, Yokoyama K, Fukuoka M et al (2005) Anti-angiogenic therapy and chemotherapy affect 99mTc sestamibi and 99mTc-HL91 accumulation differently in tumour xenografts. Nucl Med Commun 26:1067–1073
Riché F, d’Hardemare AM, Sèpe S et al (2001) Nitroimidazoles and hypoxia imaging: synthesis of three technetium-99m complexes bearing a nitroimidazole group: biological results. Bioorg Med Chem Lett 11:71–74
Ramalingam K, Raju N, Nanjappan P et al (1994) The synthesis and in vitro evaluation of a 99mtechenetium-nitroimidazole complex based on a bis(amino-phenol) ligand: comparison to BMS-181321. J Med Chem 37:4155–4163
Bormans G, Cleynhens B, Groot et al (2003) Synthesis radio-LC-MS analysis and biodistribution in mice of 99mTc-NIM-BAT. J Label Compd Radiopharm 46:575–585
Volkert WA, Hoffman TJ, Seger RM et al (1984) 99mTc-propylene amine oxime 99mTc-PnAO); a potential brain radiopharmaceutical. Eur J Nucl Med 9:511–516
Archer CM, Edwards B, Kelly JD (1995) Technetium-labeled agents for imaging tissue hypoxia in vivo. In: Nicolini M, Bandoli G, Mazzi U (eds) Technetium and rhenium in chemistry and nuclear medicine. SG Editoriali, Padova, pp 535–539
Zhang X, Melo T, Ballinger JR, Rauth AM (1998) Studies of 99mTc-BnAO (HL-91): a non-nitroaromatic compound for hypoxic cell detection. Int J Radiation Oncology Biol Phys 42:737–740
Imahashi K, Morishita K, Kusuoka H et al (2000) Kinetics of a putative hypoxic tracer, 99mTc-HL91, in a normoxic, hypoxic, ischemic, and stunned myocardium. J Nucl Med 41:1102–1107
Suzuki T, Nakamura K, Kawase T, Kubo A (2003) Monitoring of response to radiation therapy for human tumor xenografts using 99mTc-HL91 (4,9-diaza-3,3,10,10-tetramethyldodecan-2,11-dione dioxime). Ann Nucl Med 17:131–138
Kasina S (2007) Bridged aromatic substituted amine ligands with donor atoms. US Patent 7,268,220 B2, 11 Sep 2007
Chu T, Li R, Hu S et al (2004) Preparation and biodistribution of technetium-99m-labeled 1-(2-nitroimidazole-1-yl)propanhydroxyiminoamide (N2IPA) as a tumor hypoxia marker. Nucl Med Biol 31:199–203
Chu T, Hu S, Wei B et al (2004) Synthesis and biological results of the technetium-99m-labeled 4-nitroimidazole for imaging tumor hypoxia. Bioorg Med Chem Lett 14:747–749
Zhang Y, Chu T, Gao X et al (2006) Synthesis and preliminary biological evaluation of the 99mTc labelled nitrobenzoimidazole and nitrotriazole as tumor hypoxia markers. Bioorg Med Chem Lett 16:1831–1833
Mallia MB, Subramanian S, Mathur A et al (2008) On the isolation and evaluation of a novel unsubstituted 5-nitroimidazole derivative as an agent to target tumor hypoxia. Bioorg Med Chem Lett 18:5233–5237
Jalilian AR, Bineshmarvasti M (2006) Synthesis, radiolabeling and stability of new nitrophenol complexes of 99mTc as possible hypoxia imaging radiopharmaceuticals. J Radioanal Nucl Med 267:169–173
Acknowledgments
The authors thank Chymiotechnon, Ministério da Economia/POE/Prime/Proj 3/293/CLARO, Faculdade de Medicina de Coimbra for financial support.
Conflict of interest statement
The authors declare that they have no conflict of interest to the publication of this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Abrantes, A.M., Serra, M.E., Murtinho, D. et al. An insight into tumoral hypoxia: the radiomarkers and clinical applications. Oncol Rev 3, 3–18 (2009). https://doi.org/10.1007/s12156-009-0001-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12156-009-0001-z